Trials / Completed
CompletedNCT04926493
Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Patients at Increased Risk for the Development of Ventilator-associated Pneumonia in the Intensive Care Unit
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ventilator-associated pneumonia (VAP) remains the most frequent healthcare-associated infection (HAI) in the intensive care unit (ICU) and one of the most critical risk factors associated with both significant morbidity as well as mortality. Although VAP treatment relies on early and appropriate antimicrobial therapy, several preventive measures have been described in the literature in order to limit its incidence and clinical impact in the ICU. Among these, preventing biofilm formation on the inner surface of the endotracheal tube appears to hold promise. Yet there is a lack of clinical relevant data documenting a causal relation between biofilm formation and VAP. Designed to overcome this critical limitation, the BIOPAVIR study intends to provide a better structural and microbiological characterization of endotracheal tube biofilm in critically ill patients at increased risk for the development of VAP in ICU during COVID-19 pandemic.
Conditions
- Biofilm Formation
- Structural and Microbiological Characterization of Endotracheal Tube Biofilm
- Ventilator-associated Pneumonia (VAP)
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | microbiological characterization | microbiological characterization of endotracheal tube biofilm |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
- First posted
- 2021-06-15
- Last updated
- 2026-02-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04926493. Inclusion in this directory is not an endorsement.